Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Consensus Guideline on the Management of the Axilla in Patients with Invasive/In-Situ Breast Cancer. The American Society of Breast Surgeons. Updated 24 September 2019. Retrieved 3 January 2022 at https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-the-Management-of-the-Axilla.pdf?v2.
2. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61. https://doi.org/10.1001/jama.2013.278932.
3. Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263:802–7. https://doi.org/10.1097/SLA.0000000000001375.
4. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8. https://doi.org/10.1200/JCO.2015.64.0094.
5. Fan B, Pardo J, Yu-Moe CW, et al. Malpractice cases in breast surgery: an assessment of litigation involving surgeons. Ann Surg Oncol. 2021;28(13):8109–15. https://doi.org/10.1245/s10434-021-10236-2.